Across TCGA pan-cancer cohorts, IGHD2-2 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGHD2-2’s most consistent transcriptional readouts.
The strongest signal is observed in colon adenocarcinoma (COAD), where IGHD2-2 RNA is repressed in tumor relative to normal tissue. In most cancer types IGHD2-2 is over-expressed in tumor, although a few such as COAD and READ show the opposite, repressed pattern.
COAD, READ, and LUAD are the cancer types where IGHD2-2 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGHD2-2 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.